Navigation Links
Clinovo Hosted the Fourth Silicon Valley BioTalks on June 6th, 2012
Date:6/21/2012

Sunnyvale, CA (PRWEB) June 21, 2012

Over fifty healthcare industry professionals attended the fourth session of the Silicon Valley BioTalks, a panel discussion co-sponsored by Clinovo and CapGemini. The event took place on June 6th, 2012 in CapGemini South San Francisco offices and addressed how to lead a successful FDA submission.

For this fourth session “FDA Submission: The new rules”, a panel of regulatory experts shared best practices on communication the Food and Drug Administration (FDA) representatives, clinical standards, and guidelines implemented by the newly appointed FDA commissioner Margaret Hamburg. “The Silicon Valley BioTalks is a great forum to hear some very experienced clinical trial professionals", states one of the attendees.

The panel was composed of industry experts with up to 20 years experience in regulatory affairs: Dr. Urte Gayko (Nodality, VP of Regulatory and Clinical Affairs), Dr. Christine Conroy (Affymax, VP of Regulatory Affairs and GCP Compliance) and Dr. Sandra Nino-Siddens (Geron Corporation, Executive Director of Regulatory Affairs). The panel was moderated by Dr. Anne-Marie Duliege (Affymax, Chief Medical Officer). The Silicon Valley BioTalks also included a networking session to allow attendees to discuss about the latest trends and challenges in the healthcare industry with fellow life science professionals.

Clinical trial professionals attended the event to increase their knowledge on Food and Drug Administration (FDA) evolving guidelines and learn best practices for FDA submissions. ”There is a growing necessity for sponsors to submit data in standards that are recognized and easily reviewable by the FDA”, pointed out Dr. Conroy, VP of Regulatory Affairs and GCP compliance at Affymax. The abstracts of the discussion can be found on the Clinovo website.

Clinovo has direct experience with the Food and Drug Administration (FDA) and supported two FDA advisory panels for world's leading life sciences companies. Clinovo’s experts presented the conclusions of their work to FDA reviewers and convincingly answered their questions. Four companies were FDA approved following their collaboration with Clinovo.

The Silicon Valley BioTalks is a premier venue for pharmaceutical and medical device professionals to build their knowledge and expertise. Since its launch in June 2011, the Silicon Valley BioTalks gathered over 200 clinical trials professionals from the Bay Area and beyond. Clinovo and the co-organizers invited 15 influent industry experts from leading life science companies including Roche, Abbott, Affymax, Theravance and Jazz Pharmaceuticals. The next session will take place in September 2012.

Contact information
Sophie McCallum
Marketing Manager at Clinovo
408-773-6258
sophie(dot)mccallum(at)clinovo(dot)com

About Clinovo
Clinovo partners with life science companies to streamline their clinical trials, leveraging years of expertise in systems integration, open source technology and industry standards. Clinovo provides Staffing Solutions, eClinical Systems and Biometrics Services including Clinical Data Management, Electronic Data Capture, CDISC mapping and SAS Programming.
http://www.clinovo.com

About the Silicon Valley BioTalks
Silicon Valley BioTalks is a series of quarterly networking and expert discussion events. Top-tier panelists from leading pharmaceutical, biotechnology and medical device companies share their expertise and best practices on specific industry challenges. The previous sessions of the Silicon Valley BioTalks addressed the following topics: Implementing Adaptive Clinical Trials, Run Efficient Clinical Trials With Open Source Technologies and How CDISC standards streamline clinical trials.

Read the full story at http://www.prweb.com/releases/2012/6/prweb9624815.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
2. Biodel Reports Fourth Quarter Fiscal Year 2011 Financial Results
3. BioMed Realty Trust Declares Fourth Quarter 2011 Common Stock and Preferred Stock Dividends
4. InterMune to Report Unaudited Fourth Quarter Esbriet® Revenue and Business Update on January 5
5. Luminex Corporation Fourth Quarter and Full Year 2011 Earnings Release Scheduled for February 6, 2012
6. Quest Diagnostics Reports Fourth Quarter 2011 Financial Results; Provides Guidance for 2012
7. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
8. Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M
9. Cepheid Reports Fourth Quarter and Full Year 2011 Results
10. BioMed Realty Trust to Report 2011 Fourth Quarter and Year End Results
11. Sangamo BioSciences Announces Fourth Quarter and Full Year 2011 Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... (PRWEB) , ... September 19, 2017 , ... VetStem Biopharma ’s CEO and founder, ... PA, PhD in Riordan’s new book "Stem Cell Therapy: A Rising Tide". Dr. Harman ... years. They bonded over an interest in the potential of stem cell therapy and ...
(Date:9/19/2017)... (PRWEB) , ... September 19, 2017 , ... ... is pleased to announce the recipients of its 2017 Science Student Award. The ... leadership qualities, and involvement with community service defray the costs of obtaining their ...
(Date:9/18/2017)... ... September 18, 2017 , ... Transportable biomass conversion facilities and ... wood is the topic of a September 27 webinar hosted by ... of transportable biomass conversion facilities for producing biochar, briquettes, and torrefied wood, biomass ...
(Date:9/17/2017)... ... September 17, 2017 , ... GeneOne Life Science, ... Food and Drug Safety (KMFDS) for an Investigational New Drug application for a ... Syndrome coronavirus (MERS-CoV). The study in Korea represents the second clinical trial for ...
Breaking Biology Technology:
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
(Date:3/30/2017)... NEW YORK , March 30, 2017 ... by type (physiological and behavioral), by technology (fingerprint, AFIS, ... recognition, voice recognition, and others), by end use industry ... travel and immigration, financial and banking, and others), and ... Europe , Asia Pacific ...
(Date:3/27/2017)... ROCKVILLE CENTRE, N.Y. , March 27, 2017 ... by Healthcare Information and Management Systems Society (HIMSS) ... Analytics Outpatient EMR Adoption Model sm . In ... top 12% of U.S. hospitals using an electronic ... recognized CHS for its high level of EMR ...
Breaking Biology News(10 mins):